Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Mesoblast Ltd ADR (MESO)

Mesoblast Ltd ADR (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 454,018
  • Shares Outstanding, K 130,091
  • Annual Sales, $ 7,460 K
  • Annual Income, $ -98,810 K
  • 60-Month Beta 3.26
  • Price/Sales 45.32
  • Price/Cash Flow N/A
  • Price/Book 0.88
Trade MESO with:

Options Overview Details

View History
  • Implied Volatility 385.24% ( +207.28%)
  • Historical Volatility 76.33%
  • IV Percentile 99%
  • IV Rank 74.98%
  • IV High 505.30% on 07/18/22
  • IV Low 25.41% on 07/14/22
  • Put/Call Vol Ratio 0.01
  • Today's Volume 8,104
  • Volume Avg (30-Day) 1,597
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 28,439
  • Open Int (30-Day) 26,467

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.11
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +52.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +39.60%
on 07/05/22
3.72 -6.18%
on 08/03/22
+1.04 (+42.45%)
since 07/01/22
3-Month
2.14 +63.08%
on 06/30/22
3.78 -7.67%
on 05/04/22
-0.26 (-6.93%)
since 05/03/22
52-Week
2.14 +63.08%
on 06/30/22
7.66 -54.44%
on 08/13/21
-3.92 (-52.90%)
since 08/03/21

Most Recent Stories

More News
Appendix 4C Quarterly Activity Report

Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022...

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)
Mesoblast Key Opinion Leader Event Series for Investors & Analysts

Chronic Low Back Pain due to Degenerative Disc Disease...

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)
Operational Highlights and Financial Results for the Period Ended March 31, 2022

Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission...

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)
Appendix 4C Quarterly Activity Report

Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022...

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.

NVS : 85.94 (+0.43%)
MESO : 3.49 (+9.06%)
BCDA : 1.4900 (+2.76%)
ENLV : 5.11 (-0.97%)
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development

Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...

MSB.AX : 0.870 (+3.57%)
LGVN : 6.10 (+0.83%)
MESO : 3.49 (+9.06%)
SAVA : 19.42 (+10.97%)
DNLI : 37.25 (+4.20%)
ALEC : 13.12 (+0.46%)
Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript

MESO earnings call for the period ending December 31, 2021.

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board

NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)
Operational Highlights and Financial Results for the Period Ended December 31, 2021

Mesoblast Prepares for Resubmission of Biologics License Application...

MSB.AX : 0.870 (+3.57%)
MESO : 3.49 (+9.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

3rd Resistance Point 4.15
2nd Resistance Point 3.94
1st Resistance Point 3.71
Last Price 3.49
1st Support Level 3.27
2nd Support Level 3.06
3rd Support Level 2.83

See More

52-Week High 7.66
Fibonacci 61.8% 5.55
Fibonacci 50% 4.90
Fibonacci 38.2% 4.25
Last Price 3.49
52-Week Low 2.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar